Antibody Industry Trends

Biointron’s Q2 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in April, May, and June.

Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March).

Sjögren’s disease (SjD) is a chronic, systemic autoimmune disorder characterized by lymphocytic infiltration of exocrine glands, most commonly the salivary and lacrimal glands, often accompanied by multi-organ extra-glandular involvement. Despite its substantial morbidity, therapeutic intervention

Immune cell engagers (ICEs) are engineered molecules that redirect endogenous immune effector cells toward malignant targets by forming synthetic immune synapses.

Trispecific antibodies are engineered proteins that can bind to three different targets at the same time. This design allows for more complex interactions than monospecific or bispecific antibodies and can be used to improve targeting, immune cell engagement, or signaling modulation.

Angiogenesis plays a fundamental role in both physiological processes such as wound healing and reproduction, as well as in pathological contexts including tumor growth, progression, and metastasis. Vascular endothelial growth factor (VEGF) is a regulator of angiogenesis and has been a major focus i

Understanding how proteins interact with each other to form functional complexes at the atomic level is key to understanding biological processes. Progress in structural characterization, modeling, and analytical sensitivity has deepened insights into binding interfaces, multivalent interactions, an

Nanodisc-based platforms have emerged as an approach to therapeutic antibody discovery and drug development, especially for membrane protein (MP) targets such as cell surface receptors, transporters, ion channels, and membrane-bound enzymes.Recent research highlights the full potential of ther

Cancer remains a leading cause of death globally, and the projected77% increasein incidence by 2050 highlights the limitations of current therapies such as chemotherapy and radiation. Antibody-drug conjugates (ADCs), which couple monoclonal antibodies with cytotoxic drugs, emerged to imp

Despite decades of therapeutic innovation, cancer remains the second leading cause of death globally, accounting for approximately 10 million deaths annually. While conventional chemotherapeutics remain a mainstay of treatment, their nonspecific cytotoxicity often results in systemic toxicity, off-t

Single-domain antibodies (sdAbs), also known as VHH antibodies or nanobodies, are the smallest functional fragments of antibodies, consisting of a single variable domain derived from heavy-chain-only antibodies found in camelids or engineered from human immunoglobulin frameworks. Despite their small

Resistance to treatment continues to limit the long-term success of many therapies. In oncology, cancers may evade antibody-based treatments through mechanisms such as antigen loss, impaired intracellular trafficking, or suppression of immune responses. To address these challenges, researchers are d